Apixaban: a novel oral inhibitor of factor Xa

E Nutescu - American Journal of Health-System Pharmacy, 2012 - academic.oup.com
Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are
reviewed. Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid …
被引用次数：54 相关文章

[引用][C] Apixaban: A novel oral inhibitor of factor Xa

E Nutescu - American Journal of Health-System Pharmacy, 2012 - cir.nii.ac.jp
Apixaban: A novel oral inhibitor of factor Xa | CiNii Research CiNii 国立情報学研究所 学術情報
ナビゲータ[サイニィ] 論文・データをさがす 大学図書館の本をさがす 日本の博士論文をさがす English …

Apixaban: a novel oral inhibitor of factor Xa

E Nutescu - American Journal of Health-System Pharmacy, 2012 - go.gale.com
Purpose. The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are
reviewed. Summary. Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid …

Apixaban: a novel oral inhibitor of factor Xa

E Nutescu - American journal of health-system pharmacy …, 2012 - pubmed.ncbi.nlm.nih.gov
Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are
reviewed. Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid …

Apixaban: A novel oral inhibitor of factor Xa.

E Nutescu - American Journal of Health-System Pharmacy, 2012 - search.ebscohost.com
Purpose. The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are
reviewed. Summary. Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid …

Apixaban: a novel oral inhibitor of factor Xa.

E Nutescu - American Journal of Health-system Pharmacy: AJHP …, 2012 - europepmc.org
Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action. It has a
plasma elimination half-life of 12 hours and has been administered in a twice-daily dosing …